MSHO's Certified Medical Office Manager Hematology & Oncology Certification Course

MSHO's Certified Medical Office Manager Hematology & Oncology Certification (CMOM) Course

Calling all administrators who wish to become CMOM certified! MSHO is conducting the Certified Medical Office Manager (CMOM) Certification Course in partnership with the Practice Management Institute (PMI). Join us to grow your leadership and problem-solving skills. To learn more or to register, click the link below.
more information

MSHO's Board Review & Re-Certification Course

MSHO's Board Review & Re-Certification Course

Master the Latest in Oncology & Hematology! Designed for Fellows and Practicing Oncologists. Stay ahead in your field with our expertly crafted program, your ultimate resource for board exam prep and a cutting-edge review of today’s best practices in diagnosing and treating blood disorders and cancer. To learn more or to register, click the link below.
more information

June - Cancer Survivor Awareness Month

Cancer Survivor Awareness Month

June is Cancer Survivor Awareness Month and today, there are more than 18 million Americans alive with a history of cancer. This month is meant to celebrate life and encourage those still battling cancer, as well as their families, that survivorship is possible. National Cancer Survivors Month also increases awareness about life after cancer.

more information

NCCN Guidelines Updates

NCCN Guidelines Updates

June 24, 2025

NCCN Templates Updated for Head and Neck Cancers.

more information

Previous Next

Advocacy

MSHO continuously contacts legislators, provides comments to policy makers, and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education

It is important that our members are aware of meetings, webinars, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation

The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board

MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information

MSHO's 40th Anniversary KudoboardJoin Us in Celebrating 40 Years of MSHO!

As we mark this milestone anniversary, we invite you to share your memories, messages, and photos on our MSHO 40th Anniversary Kudo Board! Whether it’s a story from past meetings, a special connection you made, or a moment that stands out - your contributions will help honor our journey and shape what’s next.

Add your message today and celebrate with us! https://www.kudoboard.com/boards/36YBWnwd. 

Upcoming Events view all events

 June 2025 
SMTWTFS
1
2
3
45
67
89
1011
121314
15161718192021
22232425
262728
2930     
Fri
1
2025
August 1 - 16, 2025

Certified Medical Office Manager Hematology & Oncology Certification Course

AUGUST 1, 2, 15, 16

MSHO Office

view event details
Fri
15
2025
August 15, 2025

Fellows Dinner & Business Meeting

Explore Opportunities. Gain Insight. Shape Your Future.

Somerset Inn, Troy

view event details
Sat
16
2025
August 16, 2025

Board Review & Re-Certification Course

Somerset Inn, Troy

view event details

Latest News view all news

FDA Approves AstraZeneca & Daiichi Sankyo's Datroway (datopotamab deruxtecan or Dato-DXd) for Adult Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
06/24/2025

FDA Approves AstraZeneca & Daiichi Sankyo's Datroway (datopotamab deruxtecan or Dato-DXd) for Adult Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

FDA Approves Incyte's Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
06/23/2025

FDA Approves Incyte's Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

YesRx Work to Remove Cancer Medication Barriers in Senate Budget 2026
06/06/2025

YesRx Work to Remove Cancer Medication Barriers in Senate Budget 2026

Corporate Sponsors view all sponsors